Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) said on Friday that it has submitted an extension application to the European Medicines Agency (EMA) for a new subcutaneous formulation of Opdivo (nivolumab).
The application seeks approval across multiple previously approved adult solid tumour indications.
Validation by the EMA initiates the centralised review process.
Subcutaneous Opdivo offers faster administration times compared to the intravenous formulation and could improve the patient experience.
Phase 3 trial data supported the application, demonstrating non-inferiority in efficacy and safety.
AnnJi Pharmaceutical secures FDA Fast Track Designation for AJ201 in rare neuromuscular disease
Myosin Therapeutics' MT-125 granted US FDA Fast Track designation in glioblastoma
Boehringer Ingelheim's JASCAYD (nerandomilast) IPF treatment gains Chinese regulatory approval
ACM Biolabs reports ACM-CpG Phase 1 study findings in tumour treatment
Galera Therapeutics sells dismutase mimetics portfolio to Biossil in USD108.5m agreement
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Sanofi's efdoralprin alfa shows superior results in phase 2 study for AATD
Genflow Biosciences publishes second European patent application for SIRT6 Variant in NASH
Trellus Health signs contract with leading global CRO and expands clinical trial offerings
GSK reports positive Phase III data for low-carbon version of Ventolin inhaler
Terns Pharmaceuticals reports topline 12-week data from Phase 2 trial of TERN-601 in obesity
The Los Angeles Trust for Children's Health Appoints Dr Sarah Rodman as New Executive Director